{"classes":[{"categories":[{"measurements":[{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG000","lowerLimit":"32.8","upperLimit":"NA","value":"41.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"}],"units":"Participants"}],"description":"OS was defined as the time from the date of study treatment to the date of death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. The OS for all participants is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-clear cell Renal Cell Carcinoma (nccRCC) received 400 mg Pembrolizumab (Pembro) intravenously (IV) on Day 1 of a 42-day cycle (every 6 weeks (Q6W)) for approximately 2 years PLUS 20 mg Lenvatinib (Lenva) orally once daily (QD) on Days 1 and 22 of a 42-day cycle (Q6W). Participants continued study intervention until progressive disease or discontinuation.","id":"OG000","title":"Pembrolizumab + Lenvatinib"}],"paramType":"MEDIAN","populationDescription":"All allocated participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"Up to approximately 47 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}